David Jonathan Heineman1, Martijn Geert Ten Berge2, Johannes Marlene Daniels3, Michaël Ignatius Versteegh4, Perla Jacqueline Marang-van de Mheen5, Michael Wilhelmus Wouters6, Wilhelmina Hendrika Schreurs7. 1. Department of Surgery, Medisch Centrum Alkmaar, Alkmaar, the Netherlands. Electronic address: david.heineman@gmail.com. 2. Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands. 3. Department of Pulmonary Diseases, VU University Medical Centre, Amsterdam, the Netherlands. 4. Department of Cardiothoracic Surgery, Leiden University Medical Center, Leiden, the Netherlands. 5. Department of Medical Decision Making, Leiden University Medical Center, Leiden, the Netherlands. 6. Department of Surgical Oncology, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Amsterdam, the Netherlands; Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, the Netherlands. 7. Department of Surgery, Medisch Centrum Alkmaar, Alkmaar, the Netherlands.
Abstract
BACKGROUND: The clinical stage of non-small cell lung cancer (NSCLC) determines the initial treatment, whereas the pathologic stage best determines prognosis and the need for adjuvant treatment. In an era in which stereotactic ablative radiotherapy (SABR) has become an alternative modality to surgical intervention, clinical staging is even more important, because pathologic staging is omitted in the case of SABR. The objective of this study was to determine the concordance between clinical and pathologic stage in routine clinical practice for patients with early-stage NSCLC. METHODS: Prospective data were derived from the Dutch Lung Surgery Audit (DLSA) in 2013 and 2014. Patients with clinical stage I NSCLC who underwent surgical resection and had a positron emission tomography-computed tomography (PET-CT) scan in their clinical workup were selected. Clinical and pathologic TNM (cTNM and pTNM) stages were compared. RESULTS: From a total of 1,790 patients with clinical stage I, 1,555 (87%) patients were included in this analysis. Concordance between cTNM and pTNM was 59.9%. Of the patients with clinical stage I, 22.6% were upstaged to pathologic stage II or higher. In total, 14.9% of all patients with clinical stage I had nodal metastases, and 5.5% of all patients had unforeseen N2 disease. In patients with clinical stage T2a tumors, 21.3% had nodal metastases, 14.5% being N1 and 6.7% being N2 disease. CONCLUSIONS: Concordance between clinical and pathologic stage is 59.9%. In patients with clinical stage I NSCLC, 22.6% were upstaged to pathologic stage II or higher, which is an indication for adjuvant chemotherapy. Improvement in accuracy of staging is thus needed, particularly for these patients.
BACKGROUND: The clinical stage of non-small cell lung cancer (NSCLC) determines the initial treatment, whereas the pathologic stage best determines prognosis and the need for adjuvant treatment. In an era in which stereotactic ablative radiotherapy (SABR) has become an alternative modality to surgical intervention, clinical staging is even more important, because pathologic staging is omitted in the case of SABR. The objective of this study was to determine the concordance between clinical and pathologic stage in routine clinical practice for patients with early-stage NSCLC. METHODS: Prospective data were derived from the Dutch Lung Surgery Audit (DLSA) in 2013 and 2014. Patients with clinical stage I NSCLC who underwent surgical resection and had a positron emission tomography-computed tomography (PET-CT) scan in their clinical workup were selected. Clinical and pathologic TNM (cTNM and pTNM) stages were compared. RESULTS: From a total of 1,790 patients with clinical stage I, 1,555 (87%) patients were included in this analysis. Concordance between cTNM and pTNM was 59.9%. Of the patients with clinical stage I, 22.6% were upstaged to pathologic stage II or higher. In total, 14.9% of all patients with clinical stage I had nodal metastases, and 5.5% of all patients had unforeseen N2 disease. In patients with clinical stage T2a tumors, 21.3% had nodal metastases, 14.5% being N1 and 6.7% being N2 disease. CONCLUSIONS: Concordance between clinical and pathologic stage is 59.9%. In patients with clinical stage I NSCLC, 22.6% were upstaged to pathologic stage II or higher, which is an indication for adjuvant chemotherapy. Improvement in accuracy of staging is thus needed, particularly for these patients.
Authors: Mark W Hennon; Luke H DeGraaff; Adrienne Groman; Todd L Demmy; Sai Yendamuri Journal: Eur J Cardiothorac Surg Date: 2020-05-01 Impact factor: 4.191
Authors: Otto C Burghuber; Klaus Kirchbacher; Andrea Mohn-Staudner; Maximilian Hochmair; Marie-Kathrin Breyer; Michael Studnicka; Michael Rolf Mueller; Petra Feurstein; Andrea Schrott; Bernd Lamprecht; Josef Eckmayr; Friedrich Renner; Josef Bolitschek; Wolfgang Pohl; Peter Schenk; Peter Errhalt; Peter Cerkl; Bernhard Baumgartner; Meinhard Kneussl; Sylvia Hartl Journal: Clin Med Insights Oncol Date: 2020-09-10
Authors: John M Varlotto; Isabel Emmerick; Rick Voland; Malcom M DeCamp; John C Flickinger; Debra J Maddox; Christine Herbert; Molly Griffin; Paul Rava; Thomas J Fitzgerald; Paulo Oliveira; Jennifer Baima; Rahul Sood; William Walsh; Lacey J McIntosh; Feiran Lou; Mark Maxfield; Negar Rassaei; Karl Uy Journal: Front Oncol Date: 2020-05-26 Impact factor: 6.244